NRX Pharmaceuticals, Inc. current report, 17 November 2018

SEC Filing Summary: Big Rock Partners Acquisition Corp.

Business Context and Reporting Period

This Form 8-K was filed on November 17, 2018, by Big Rock Partners Acquisition Corp. (the "Company"), a Delaware corporation and emerging growth company. The filing reports on material agreements entered into on November 17, 2018, and a promissory note issued on November 20, 2018, to secure extensions of time to consummate a business combination. Note: The input metadata referenced "NRX Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Big Rock Partners Acquisition Corp.

Key Financial Metrics and Obligations

  • Debt: The Company issued an unsecured promissory note on November 20, 2018, in the original principal amount of $690,000 to BRAC Lending Group LLC (the "Investor").
  • Interest: The Note does not bear interest.
  • Maturity: The Note matures upon the closing of a business combination.
  • Equity Transfer: The Sponsor transferred 1,500,000 shares of common stock ("Insider Shares") to the Investor for $1.00 cash consideration.
  • Liquidity Support: The Sponsor agreed to loan funds for non-business combination expenses, with a repayment cap of $200,000 upon a successful business combination.

Material Changes and Agreements

The Company entered into an agreement to extend its deadline to consummate a business combination up to two times for an aggregate of up to six months. The first three-month extension was announced to run from November 22, 2018, to February 22, 2019. The $690,000 Note was issued to fund this first extension. Additionally, the Investor agreed to loan funds necessary for business combination expenses, which will be added to the Note.

Outlook, Risks, and Contingencies

  • Debt Forgiveness: If the Company fails to consummate a business combination, the outstanding debt under the Note will be forgiven, except for funds held outside the trust account after paying other fees and expenses.
  • Sponsor Liability: The Sponsor agreed to be responsible for all Company liabilities as of November 17, 2018, excluding shareholder redemption liabilities.
  • Expense Repayment: If a business combination is not consummated, all outstanding loans from the Sponsor for non-business combination expenses will be forgiven.
  • Escrow: The transferred Insider Shares remain in escrow subject to the terms of the Stock Escrow Agreement.

Investor Verification Checklist

  • Verify the exact terms of the promissory note (Exhibit 10.5) regarding the conditions for debt forgiveness.
  • Confirm the status of the trust account and funds available for shareholder redemptions versus the $690,000 note obligation.
  • Review the Stock Escrow Agreement (Exhibit 10.2) to understand restrictions on the 1,500,000 Insider Shares.
  • Monitor the Company's progress toward a business combination by the February 22, 2019, deadline to determine if further extensions or liquidation will occur.